Safety of Macitentan for the Treatment of Portopulmonary Hypertension: Real-World Evidence from the Combined OPUS/OrPHeUS Studies

• DOI: 10.1007/s41030-023-00251-x
• Publication Date: 2024-01-07T04:16:41Z
• Authors: Nick H. Kim; Kelly M. Chin; Vallerie V. McLau...; Hilary DuBrock; Ricardo Restrepo-...; Zeenat Safdar; Gwen MacDonald; Nicolas Martin; Daniel Rosenberg; Maria Solonets; Richard Channick
• Keywords: Portopulmonary hypertension; Opus; Real world evidence

Portopulmonary hypertension (PoPH) carries a worse prognosis than other forms of pulmonary arterial (PAH). Data regarding use PAH-specific therapies in patients with PoPH are sparse as they usually excluded from clinical trials. This analysis describes patient characteristics, treatment patterns, outcomes, and safety profiles newly initiating macitentan the USA using OPUS/OrPHeUS combined dataset.